Advanced search
Publication Cover
Core Evidence Volume 12, 2017 - Issue
Journal homepage
147
Views
5
CrossRef citations to date
0
Altmetric
Review

Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy

Thomas Karagiannis1 Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, GreeceCorrespondence[email protected]
,
Eleni Bekiari1 Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece
&
Apostolos Tsapas1 Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Aristotle University of Thessaloniki, Thessaloniki, Greece;2 Harris Manchester College, University of Oxford, Oxford, United Kingdom
Pages 1-10 | Published online: 15 Mar 2017

Citations (5)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (1)

Taichi Minami, Akiko Kameda & Yasuo Terauchi. (2021) An evaluation of canagliflozin for the treatment of type 2 diabetes: an update. Expert Opinion on Pharmacotherapy 22:16, pages 2087-2094.
Read now

Articles from other publishers (4)

Saad U Rehman & Faiqa Rahman. (2020) Evidence-Based Clinical Review on Cardiovascular Benefits of SGLT2 (Sodium-Glucose Co-Transporter Type 2) Inhibitors in Type 2 Diabetes Mellitus. Cureus.
Crossref
Kyu Hang LeeSang Don LeeNamdu KimKwee Hyun SuhYoung Hoon KimSang Soo Sim. (2019) Pharmacological evaluation of HM41322, a novel SGLT1/2 dual inhibitor, in vitro and in vivo . The Korean Journal of Physiology & Pharmacology 23:1, pages 55.
Crossref
Atsushi Tanaka & Koichi Node. (2017) Increased amputation risk with canagliflozin treatment: behind the large cardiovascular benefit?. Cardiovascular Diabetology 16:1.
Crossref
Mihoko Matsumura, Yuki Nakatani, Seiichi Tanka, Chie Aoki, Masaaki Sagara, Kazunori Yanagi, Kunihiro Suzuki & Yoshimasa Aso. (2017) Efficacy of Additional Canagliflozin Administration to Type 2 Diabetes Patients Receiving Insulin Therapy: Examination of Diurnal Glycemic Patterns Using Continuous Glucose Monitoring (CGM). Diabetes Therapy 8:4, pages 821-827.
Crossref

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.